Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Investor Presentation (March 2022)
12 slides from Indivior Pharmaceuticals's investor presentation, Mar 31, 2022
Slide 1: US Additional Listing Considerations
US Additional Listing Considerations March 31, 2022
Slide 2: Indivior participants
Indivior participants Graham Hetherington Mark Crossley Ryan Preblick Chair Chief Executive Officer Chief Financial Officer 2
Slide 3: Context for shareholder consultations
Context for shareholder consultations ✓ Indivior today ✓ Rationale for additional US listing ✓ Work and analysis undertaken to date ✓ Process ✓ Governance ✓ Next steps 3
Slide 4: Well-positioned to realize Indivior's upside potential
Well-positioned to realize Indivior’s upside potential Created greater Commercialized Strengthening Refreshed board & certainty growing LAIs our pipeline leadership Settled US Government SUBLOCADE® for AEF0117 targeting Established clear (DOJ/HHS-OIG/FTC) legal opioid use disorder cannabis-related d
Slide 5: US opioid crisis worsening with elevated overdose deaths driven by fentanyl
US opioid crisis worsening with elevated overdose deaths driven by powerful synthetic opioids (fentanyl) US Overdose Deaths Accelerated During COVID US Opioid Use Disorder (2015 – Oct. 2021) (OUD) remains undertreated 105,752 ➤ 10 mil.+ people(1) 16% YOY Total Overdose 79,481 ➤ 17% YOY Opioid Engage
Slide 6: Rationale for additional US listing
Rationale for additional US listing Better aligned with Group Strategy, Structure and Opportunity NET REVENUE FY 2021 ➤ US currently is, and is expected to remain, the Group’s largest and highest value market for its key treatments (SUBLOCADE® and PERSERIS®) 24% ➤ Largest healthcare / biopharma inve
Slide 7: Detailed work undertaken
Detailed work undertaken Approximately six months of detailed analysis and expert adviser input to date Key areas analyzed Expert Advisors Engaged ➤ Capital markets ➤ Corporate Brokers: Morgan Stanley ➤ Indexation & Jefferies ➤ Governance ➤ Legal: Freshfields Bruckhaus Deringer ➤ Regulation LLP (UK
Slide 8: Proposed consultation on possible additional US listing
Proposed consultation on possible additional US listing Current consultation focuses on an additional US listing; further assessment of value of US primary /sole listing would follow if deemed appropriate Current Focus ➤ Additional listing (alongside current LSE listing) on a major US exchange Addit
Slide 9: Current additional US listing consultation
Current additional US listing consultation Considerations Governance ➤ Additional listing of Indivior shares on ➤ Governance will remain subject to and report a major US stock exchange (NYSE, NASDAQ) against UK Listing Rules, UK Disclosure and Transparency Rules and UK Corporate Governance ➤ Full Pr
Slide 10: Expected additional US listing timeline
Expected additional US listing timeline* Spring / Summer July September Spring 2022 2022 2022 2023 Shareholder Board decision whether Early September: Implementation and consultations to proceed with EGM circular published commencement of shareholder vote (likely additional US listing in conjunction
Slide 11: Key contacts
Key contacts Jason Thompson, VP Investor Relations +1 804 402 7123 Tim Owens, Dir. Investor Relations +1 804 263 3978 Kathryn Hudson, Company Secretary +44 (0)1753 423940 11
Slide 12: Thank you
So INDIVIOR